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The aim of this European initiative is to facilitate a structured discussion to improve the next edition of
the International Classification of Sleep Disorders (ICSD), particularly the chapter on central disorders of
hypersomnolence.
The ultimate goal for a sleep disorders classification is to be based on the underlying neurobiological
causes of the disorders with clear implication for treatment or, ideally, prevention and or healing. The
current ICSD classification, published in 2014, inevitably has important shortcomings, largely reflecting
the lack of knowledge about the precise neurobiological mechanisms underlying the majority of sleep
disorders we currently delineate. Despite a clear rationale for the present structure, there remain
important limitations that make it difficult to apply in routine clinical practice. Moreover, there are in-
dications that the current structure may even prevent us from gaining relevant new knowledge to better
understand certain sleep disorders and their neurobiological causes.
We suggest the creation of a new consistent, complaint driven, hierarchical classification for central
disorders of hypersomnolence; containing levels of certainty, and giving diagnostic tests, particularly the
MSLT, a weighting based on its specificity and sensitivity in the diagnostic context.
We propose and define three diagnostic categories (with levels of certainty):chterweg 5, Heemstede, the Netherlands. Fax: þ31 23 558 8908.
rk for Narcolepsy, CHU Gui de Chauliac, 80 Augustin Fliche, 34295 Montpellier Cedex 5, France.
ers), ydauvilliers@yahoo.fr (Y. Dauvilliers).
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ICSD/ICSD3 International classification of sleep disorders/3rd
edition
IH Idiopathic hypersomnia
MSLT Multiple sleep latency test
NT1 Narcolepsy type 1
NT2 Narcolepsy type 2
OSA Obstructive sleep apnea
PLMS/PLMD Periodic limb movement syndrome/Periodic limb
movement disorder
PSG Polysomnography
PVT Psychomotor vigilance test
RBD REM sleep behaviour disorder
RIA Radioimmunoassay
RLS Restless legs syndrome
SART Sustained attention to response task
SOREM Sleep onset REM episode
SP Sleep paralysisIntroduction
The goal of a classification
The ultimate goal for a sleep disorders classification is to be
based on the underlying neurobiological causes of the disorders
with clear implication for treatment or, ideally, prevention and
healing.
Currently, most sleep specialists refer to the International
Classification of Sleep Disorders 3rd edition (ICSD3), published in
2014 to diagnose and classify sleep disorders [1]. This classification
inevitably has important shortcomings, largely reflecting the lack of
knowledge about the precise neurological mechanisms underlying
the majority of sleep disorders we currently delineate. Despite a
clear rationale for the present structure, there remain important
limitations that make it difficult to apply in routine clinical practice.
Moreover, the current structure may prevent us from gaining
relevant new knowledge to better understand certain sleep disor-
ders and their neurobiological causes.
This “position paper” addresses sleep disorders in adults and
discusses shortcomings in the approach and structure of the ICSD3
in general with subsequent focus on the chapter: “Central disorders
of hypersomnolence”. By dissecting the inconsistencies and
shortcomings of the current classification, and taking into account
recently obtained knowledge, we produce suggestions for an
adjusted and updated section on hypersomnolence.
The aim of our “position paper” is primarily to facilitate dis-
cussions in order to:
1) Improve a new version of the classification for practical use
2) Define a research agenda in this area, aiming to explore further
neurobiological causes and substrates for sleep-wake com-
plaints and their underlying disordersGeneral comments on the current ICSD3 classification
Some of our comments on the chapter “Central disorders of
hypersomnolence” deal with the general structure:
For the classification of some disorders, such as insomnia and
restless legs syndrome (RLS), the diagnosis is based solely on sub-
jective complaints whereas for others, such as narcolepsy type 1, it
presumes a precise pathophysiology. In others such as obstructive
sleep apnea (OSA), diagnosis can be solely defined by findings on
ancillary investigations (i.e., AHI).
There are no levels or grades of certainty defined for the various
diagnoses.
There are hardly measures of severity for sleep-related symp-
toms included.
Several potentially important assessments that can be clinically
useful and easy to apply are not listed as mandatory in confirming
or refuting diagnoses, largely due to problems of reimbursement in
many countries including the US. Examples include actigraphy,
hypocretin measurements, and HLA typing.
Comments on the chapter “Central disorders of hypersomnolence”
Terminology and consistency
The chapter is titled “Central disorders of hypersomnolence” but
contains a variety of disorders such as “Insufficient Sleep syn-
drome” that generally have no “central” cause, but are primarily
related to behaviour or lifestyle. In contrast, OSA as one the most
prevalent causes of hypersomnolence is not listed although it may
be argued that there is usually no central origin for OSA.
It is presumed that introducing the word “Hypersomnolence” in
ICSD3, after its introduction in DSM-5 in 2013 [2], was intended to
solve previous inconsistencies around other similar terms such as
“excessive daytime sleepiness”, “hypersomnia”, and “excessive
G.J. Lammers et al. / Sleep Medicine Reviews 52 (2020) 101306 3sleepiness”. However, it has led to potential further confusion as
“hypersomnolence” is used to describe both the symptom of
“excessive sleepiness” and to define a group of disorders: “Central
disorders of hypersomnolence”. This chapter then documents dis-
orders such as “idiopathic hypersomnia” but not, for example,
“idiopathic hypersomnolence” or “Idiopathic excessive sleepiness”.
“Hypersomnolence” as defined in the DSM-5 is very similar towhat
used to be the definition of “hypersomnia”. Compared to ICSD3, it
covers a larger variety of possible expressions of daytime sleepiness
including an increased need for sleep, but it is confusing that it is
used only to describe expressions of “Hypersomnolence disorders”
and is not meant to be applied to narcolepsy although narcolepsy
may have largely overlapping expressions.
From their original meanings, excessive daytime sleepiness
(EDS) and hypersomnia are qualitatively different complaints
[3e5]. This is not taken into account in ICSD3 and the distinction is
blurred by use of the term “Hypersomnolence”. In this manuscript,
we use “hypersomnolence” as an overarching description for the
presence of EDS and/or excessive need of sleep (ENS) or an
increased quantity of sleep (see also the definition section).
Hypersomnolence is not just characterized by “daily episodes of
an irrepressible need to sleep or daytime lapses into sleep” as in the
definition described by ICSD3. The term usually harbours much
more in the way of disabling symptoms. Accordingly, it often in-
cludes impaired vigilance or sustained attention; automatic be-
haviours; cognitive complaints, especially linked to poor memory;
and it can be accompanied by increased need for sleep and severe
sleep inertia [6e8].
An increased need for sleep as a separable symptom is not
defined. There is also no clarification in distinguishing it from cli-
nophilia: the tendency to remain in bed in a reclined position
without increased actual sleep time when objectively assessed.
There is no explicit statement about the difference between
fatigue and hypersomnolence. Fatigue may accompany EDS and
hypersomnia, but it is a qualitatively different complaint and never
a (core) symptom of a disorder of hypersomnolence, although it
may accentuate the impairment caused by it [9].
As mentioned, attentional problems may be an expression of
hypersomnolence. However, there is no guidance as how to sepa-
rate conditions considered to be “pure” attention deficit disorders
such as attention deficit hyperactivity disorder (ADHD) from
complaints of attention deficit as an expression of a disorder of
hypersomnolence [10].Diagnostic criteria and tests
There are no clear criteria to assess or measure sleep deprivation
and circadian rhythm disturbances as potential causes for hyper-
somnolence although it is stated that they should be excluded
before making the diagnosis of idiopathic hypersomnia, for
example.
The current classification relies heavily on the MSLT result
despite the test having low sensitivity and specificity for diagnostic
purposes [11e13]. Moreover, more recently, the consistency of the
MSLT result over time is suggested to be unreliable for several di-
agnoses (see also below) [14e16].
The ability of the MSLT to quantify sleepiness has only been
validated in healthy volunteers with different degrees of sleep
deprivation [17e20]. It is, therefore, questionable whether it is
justified to base diagnostic categories heavily depending on MSLT
results [17] and not taking age effects into account [21].
In clinical practice, it is not uncommon for a single patient to
havemultiple potential causes or contributors of hypersomnolence,
including sleep deprivation, OSA, and depressed mood as common
examples. It would be helpful to include a paragraph in theclassification regarding this issue. This highlights our lack of
knowledge on the difficult question of whether depression is a
primary cause of hypersomnolence in individual patients, espe-
cially given how in many, it fuels symptoms of insomnia [22e24].
It is frequent that depression may be comorbid in narcolepsy
type 1 but must be excluded in type 2 and idiopathic hypersomnia.
It is not clear why narcolepsy type 1 should be diagnosed only
when the symptoms are present for at least 3 mo whenwithin this
period there is clear-cut cataplexy or established hypocretin
deficiency.
Relevant new knowledge and remaining unsolved issues
New knowledge
It is known for many years that the sensitivity and specificity of
MSLT criteria as used in ICSD3 are acceptable in narcolepsy type 1
and, importantly, appear relatively consistent over time [14e16,25].
In contrast, and assessed in more recent studies, the test's sensi-
tivity, specificity and particularly consistency over time are much
less secure for the currently defined disorders: narcolepsy type 2,
IH and chronic sleep deprivation [14,25,26].
Recent studies indicate that the sequence of sleep stages as
assessed during MSLT testing may have diagnostic significance
[26e28]. REM sleep occurring before stage 2 sleep is indicative of
narcolepsy type 1, for example.
It may be diagnostically very helpful to observe video footage of
provoked cataplexy although this approach is clearly labour
intensive and only suitable for patients with frequent cataplexy
attacks [29,30].
There are indications that prolonged sleep recordings and ob-
servations may offer additional diagnostic information and
improve classification. However, the expense and labour intense
nature of prolonged recording is likely to limit overall acceptance
and standardization of results may be difficult [31].
Issues to be solved in a new classification of Sleep-Wake disorders
It remains unclear how chronic sleep deprivation can reliably be
assessed or excluded as a relevant factor. Actigraphymay be helpful
but criteria and protocols for assessing the effects of sleep exten-
sion, for example, are lacking.
It is also unclear how circadian disorders should be reliably
assessed or ruled out as causes for EDS in the absence of precise
criteria and diagnostic protocols.
As currently defined, it is very likely that the currently defined
disorder IH is a heterogenous entity. It appears sensible to separate
a phenotype with an increased need for sleep from a phenotype
without [3e5].
It is unclear whether the currently defined disorders IH and
narcolepsy type 2 are always separable entities [32]. Moreover, it is
not known if EDS in narcolepsy type 2 can be distinguished reliably
from expressions of chronic sleep deprivation and narcolepsy type
1 [14,26,33].
We know that narcolepsy with cataplexy can start as narcolepsy
without cataplexy but we have poorly identified reliable predictors
which might include HLA typing (DQB1*06:02). Currently, only
hypocretin deficiency is known to be associated with a risk of
subsequent cataplexy [34].
Narcolepsy type 1 & 2, and IH are currently largely defined and
separated by MSLT criteria. We know that the result of the MSLT
may change over time particularly in narcolepsy type 2 and IH.
However, the contributory effects of different levels of sleep
deprivation, including night shifts, in the days andweeks before the
individual test is performed are unknown. To clarify if the MSLT is,
indeed, a relatively inadequate test for accurately diagnosing
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guidelines how to exclude sleep deprivation in the week(s) before
performing a MSLT.
Given the current importance of the MSLT in defining whether a
subject suffers from IH or narcolepsy type 2, changes in MSLT re-
sults over time will effectively change a diagnosis, even if the
clinical picture is stable.
Mindful that the sensitivity and specificity of theMSLT is low for
IH and narcolepsy type 2, we should allow a different approach in
future classifications for patients who have genuine complaints of
hypersomnolence but fail to have diagnostic MSLT results.
There is a need for an international standardization for
measuring hypocretin levels.
In order to solve most of the issues raised, a new consistent,
complaint driven, hierarchical classification, containing levels of
certainty, and giving diagnostic tests, particularly the MSLT, a
weighting based on its specificity and sensitivity in the diagnostic
context is proposed.Methods
A European Task Force to develop an updated guideline for the
treatment of narcolepsy, endorsed by the European Neurological
Association (EAN), the European Sleep Research Society (ESRS) and
the European Narcolepsy Network (EU-NN), was established in
2017. Besides primary discussions concerning treatment and
management of narcolepsy, issues were raised concerning diag-
nostic uncertainties when applying the ICSD3 during initial meet-
ings in Lugano (2017), Montpellier (2018), Boston (2018), and Bern
(2019). The current paper summarizes these discussions and con-
clusions. Regarding the provided definitions and recommenda-
tions: they are all ultimately based on consensus and expert
opinion, but for all PubMed searches (period 1979eApril 2019)
have been performed first (by GJL, CB and YD), using the respective
appropriate searching terms. “Excessive sleepiness”, “Daytime
sleepiness”, “Hypersomnolence”, “Hypersomnia”, “Cataplexy”,
“Narcolepsy AND diagnostic criteria”, “Idiopathic hypersomnia
AND diagnostic criteria”, “Multiple Sleep Latency Test”, “Sustained
attention AND sleep”, “Fatigue”, “Automatic behaviour”, “Clino-
philia”, “Sleep inertia”, Sleep drunkenness”, “Sleep attack”, “Long
sleeper”, “Hypocretin”, “Orexin”, “HLA narcolepsy”, “Narcolepsy
biomarkers”, If recommendations are solely based on expert
opinion it is explicitly stated in the text. The three main authors
(GJL, CB, YD) prepared a first, second and third draft which were
then sent for review and revised by the task force. Consensus on all
statements could be reached.3 This is the definition of the core problem. It must be acknowledged that EDS has
multiple dimensions as explained in chapter 1.1.1.
4 The cut-offs of nine respectively 10 h are based on expert opinion. They are
supported by several publications and the DSM-5 and the previous edition of the
ICSD [2,35,36]. However, additional knowledge is needed. Large data sets such as
the Database of the European Narcolepsy Network that also includes information
on other hypersomnolence disorders may provide these data in the near future.
Machine learning could support delineation of cut-off scores [37].
5 The cut-off score is expert opinion. It is highly unlikely that a completely
healthy person will need more than 12 h of nocturnal sleep.The approach
There is a focus on:
- Expressions of hypersomnolence as a specific symptom, and on
cataplexy as specific marker for the only central disorder of
hypersomnolence with an established cause, namely, hypo-
cretin deficient narcolepsy.
- Other symptoms such as hypnagogic hallucinations and sleep
paralysis are not considered in depth given their low diagnostic
specificity for any particular cause of hypersomnolence.
- Adults.
Principles:
- First: we provide full definitions for the various concepts
discussed.- Second: the primary complaint of the patient is the starting
point of any diagnostic process.
- Third: the potential multiple dimensions of the complaint of
hypersomnolence are taken into account.
- Fourth: severity of complaints and degrees of certainty of a
particular diagnosis are taken into account.
- Fifth: relevant new knowledge obtained after the publication of
the ICSD3 in 2014 is taken into account, particularly regarding
MSLT data
- Sixth: with the exception of narcolepsy type 1, we advocate a
hierarchical approach to the diagnostic process by first
excluding sleep deprivation, then sleep apnea and subsequently
circadian rhythm disorders before considering a diagnosis of
hypersomnolence
- Seventh: a diagnosis may shift to different levels of certainty or
categories over time, depending on changes in symptoms or the
results of additional diagnostic tests.Definitions (alphabetical)
Attention problems: difficulties with sustaining a purposeful
focus on stimuli.
Automatic behaviours: behaviours that are performed without
conscious knowledge or full voluntary control.
Clinophilia/high levels of bed rest: the tendency to spend
prolonged amounts of time reclined in bed without objective evi-
dence for increased sleep time.
Excessive daytime sleepiness (EDS)3: the complaint of
an inability to stay awake during the normal wake period of
the day.
Excessive need for sleep (ENS)4: the complaint of a need
for an excessive quantity of sleep over the full 24 h period. At
least 10 h of sleep are needed over 24 h of the day with the
nocturnal component providing at least 9 h. The complaint for
increased need for sleep must be, associated with impairment
and distress related primarily to deteriorated quality of daytime
wakefulness, and cannot be (fully) resolved by increasing the
amount of sleep.
Fatigue: the complaint of physical and/or mental exhaustion
with difficulties in initiating or sustaining voluntary activities that
are not significantly improved by increased rest or sleep.
Hypersomnia: the objectified complaint of ENS. An objective
assessment of an excessive quantity of sleep: at least 10 h of sleep
duration over 24 h of the day with the nocturnal component
providing at least 9 h of sleep duration.
Hypersomnolence: the presence of a complaint of EDS and/or
ENS.
Long sleeper5: a person with a constitutional need for more
sleep than average, reflected in a habitual long nocturnal sleep
period of up to 12 h in the absence of daytime complaints when this
amount of sleep is fully achieved.
Nap: a short period of sleep during the wake period of the day.
Sleep attack: a relatively sudden occurring unintended nap, not
preceded by a feeling of sleepiness.
G.J. Lammers et al. / Sleep Medicine Reviews 52 (2020) 101306 5Sleep deprivation: a situation inwhich a person is not achieving
a sufficient amount of nocturnal sleep as determined by their in-
dividual constitutional requirements.
Sleep inertia and drunkenness: the complaint of difficulty in
achieving complete wakefulness at the end of a sleep period,
potentially accompanied by confusion, disorientation, and poor
motor coordination or even ataxia. Sleep drunkenness is consid-
ered as a severe manifestation of this phenomenon [8].
Unintended nap: an episode of irresistible sleep, which
may occur at any time during the wake period of the day, but
most commonly associated with tedious or monotonous
activities.7 This recommendation is expert opinion supported by the referred study.
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Results
The result of applying the first four principles is described
below. The clinical phenotyping results from history taking rather
than from the use of questionnaires.
1) Hypersomnolence
Hypersomnolence may present in two forms, EDS and ENS.
1.1.1 Manifestations of excessive daytime sleepiness (EDS)
Clinical symptoms/complaints:
1) The presence of a feeling of daytime sleepiness throughout most
of the day as opposed to symptoms of fatigue
2) Inability to stay awake in monotonous situations with unin-
tended napping and possibly sleep attacks
3) Acquired need for scheduled napping during the day
4) Difficulty with sustained attention and vigilance
5) Automatic behaviours that can be attributed to EDS
EDS often is accompanied by cognitive difficulties, particularly
memory complaints, and emotional difficulties, including irrita-
bility and distractibility. Headache complaints are also likely to be
commoner.
Criteria for presence of EDS
There is a daily or near daily presence of symptom 2 OR there is
the daily presence of symptom one and at least one of the other
symptoms listed.
1.1.2 Manifestations of excessive need for sleep (ENS) in adults
Clinical symptoms/complaints:
1) An increased need for sleep in normal daily life. The need must
comprise at least 10 h of sleep per 24 h and/or at least 9 h of
nocturnal sleep6 AND
2) The presence of at least one of the listed symptoms of EDS and/
or the presence of sleep inertia/sleep drunkenness, AND
3) Sleep extension will not (fully) eliminate the symptoms/com-
plaints of 2.
Criteria for presence of ENS
There is a daily or near daily presence of all three listed symp-
toms/complaints.6 The defined cut-offs are based on expert opinion and in line with definition
used in DSM-V.1.2.1 Severity of EDS
Subjective assessment.
1) For example the score on the Epworth Sleepiness Scale
2) Frequency of voluntary and involuntary naps (per day/perweek)
3) Presence of complications that can be attributed to EDS
(cognitive symptoms, lapses, accidents)
Of note: the presence of co-morbid fatigue may increase the
burden of EDS.
Objective assessment.
1) Mean sleep latency by MSLT <2e5 min; 5e8 min; > 8 min)
2) Results of vigilance test (SART)
1.2.2 Severity of ENS
Subjective assessment.
1) The number of hours of sleep needed over 24 h when given the
full opportunity to sleep as compared to the amount of sleep
normally obtained in the pre-symptomatic period
2) frequency/duration of inertia/sleep drunkenness following a
nocturnal sleep period and a nap
Objective assessment.
1) the amount of sleep per 24 h as estimated with two weeks of
actigraphy/sleep log and confirmed by a ambulant PSG
recording of at least 32 h allowing ad libitum sleep, or at least
32 h clinical PSG recording in standardized conditions also
allowing ad libitum sleep [31].7
2) Cataplexy
2.1.1 Presence of typical or unambiguous partial cataplexy (history
taking8) [38e42]
1) Bilateral loss of muscle tone in face, neck or legs (buckling
knees), with or without involvement of the arms, in the absence
of falls or collapse
2) Events triggered by sudden emotions, particularly of a positive
nature related to mirth. Typical situations include laughing out
loud or telling an amusing story/joke; making a witty remark; or
pleasant surprise when unexpectedly meeting a familiar ac-
quaintance. Other situations include weakness induced by
orgasm or occasionally anger. It is most reliably diagnosed if
triggers other than laughter can be identified given the significant
number of healthy people who report a degree of generalised
weakness induced by laughter, particularly in the legs [40,42].
3) Duration of episodes from about a second up to 1min for a single
attack, typically less than 30 s. Sequential attacks caused by a
persisting precipitant trigger may have a much longer duration.
4) Preserved level of consciousness.
5) Abrupt return of muscle activity after the attack.
6) It is very common to have a second attack in the months after an
initial episode unless treatment immediately startedThere is debate whether cataplectic attacks always start in the neck and face,
and also if muscle jerking or twitches are part of the typical clinical picture of
cataplexy although observations made by experts lend support to this view.
However, since we rely on history taking and not all patients experience these
observations, these elements are not part of the mandatory criteria.
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tory taking8) [38e42]
1) Bilateral progressive loss of muscle tone generally starting in the
face or neck and building up over seconds, leading to a fall to the
ground with buckling of the legs
2) Events triggered by sudden emotions, particularly of a positive
nature related to mirth. Typical situations include laughing out
loud or telling an amusing story/joke; making a witty remark; or
pleasant surprise when unexpectedly meeting a familiar ac-
quaintance. Other situations include weakness induced by
orgasm or occasionally anger. It is most reliably diagnosed if
triggers other than laughter can be identified given the significant
number of healthy people who report a degree of generalised
weakness induced by laughter, particularly in the legs [40,42].
3) Duration of an episode typically lasts several seconds and up to
2 min. In exceptional cases, sequential attacks may have a much
longer duration.
4) Preserved level of consciousness
5) Abrupt return of muscle activity after the attack
Supportive criteria [40]:
- Quick clinical response to anti-cataplectic drugs, particularly
antidepressants such as clomipramine or venlafaxine
- Muscle tendon areflexia/H-reflex suppression, particularly dur-
ing generalized episodes [41e43].
Compatiblewith typical cataplexy (if criteria above are alsomet)
[39,40]:
- Occasionally spontaneous episodes
- Facial twitching
- Prolonged episodes after discontinuation of anti-cataplectic
drugs (except sodium oxybate)
- Attacks experienced as asymmetrical but not strictly unilateral
- A generalized attack may occasionally result in a full-blown
sleep episode
2.2 Severity of cataplexy
By history.
1) Frequency of cataplexy episodes with ranges typically quantified
as less than one per month to more than five per day [44].
2) Typical duration of episodes
3) Presence or absence of generalized attacks (e.g., associated with
falls)
4) Subjective levels of disability caused by episodes of cataplexy,
taking into account the typical situations in which they occur
(e.g., at workplace)
2.3 Certainty of typical cataplexy
The optimal method for confirming the presence of cataplexy
relies on direct observation by an experienced clinician in real life
or, more typically, from recorded video material [29,30].
Unfortunately, direct or recorded observations are rare to wit-
ness in adult patients and reliance is placed on accurate history
taking. Only descriptions fulfilling all characteristics above can be
considered as typical cataplexy.
Cataplexy should still be considered, but as atypical, if the pa-
tient reports one of the following features during history taking:
- attacks are purely unilateral or unusually prolonged in the
absence of the precipitant (>3 min)- no clear precipitants for episodes or if only negative emotions
act as triggers
- it is uncertain whether consciousness is fully preserved
- hyperacute generalised muscle weakness without build-up over
seconds, leading to falls and injuries.
- only generalized attacks
- it takes minutes or longer to recover after a single attack
If more than one of the above listed characteristics is present the
attacks must be considered to be “cataplexy-like” attacks. In all
such cases, themeasurement of hypocretin-1 in CSFmay be helpful,
as presence of low hypocretin favours presence of cataplexy and
high levels of hypocretin decreases probability of cataplexy.
Cataplexy is generally excluded if there is no doubt that loss of
consciousness or awareness occurs at the onset of episodes.
3) Proposal for a new classification of central disorders of hy-
persomnolence in adults
We believe the current ISCD3 guidelines on central causes of
hypersomnolence have created a degree of diagnostic confusion by:
- not consistently taking the symptomatic complaint of the pa-
tient as a starting point
- not emphasising the importance or impact of chronic sleep
deprivation in the clinical assessment of hypersomnolence and
its influence on the results of ancillary investigations
- incorporating the detailed results of the MSLT as primary diag-
nostic criteria for certain categories of hypersomnolence
The exaggerated and arguably unjustified central role for MSLT
results to influence diagnosis has over-shadowed the importance
and relevance of detailed clinical characteristics in disorders
causing hypersomnolence. Moreover, it has stifled the search for
updated and more accurate diagnostic strategies.
We argue that progress will depend on more descriptive diag-
nostic categories that permit changes in MSLT results over time
without necessarily producing differing diagnostic labels. Wewould
also advocate the introduction of “probable” diagnoses when the
MSLT result is intermediate and potentially alternative explanations
or diagnoses such as chronic sleep deprivation, OSA and circadian
disorders after these have been adequately addressed. However, we
advocate to avoid the use of “possible” diagnosis to prevent confu-
sion for patients and health insurance companies (a diagnosis
labelled as “possible”might be interpret to be uncertain or unclear).
Finally, it should be acknowledged that problems of sustained
attention or vigilance may be the most disabling aspects of patients
with hypersomnolence, as opposed to sleepiness per se.
With the previous discussions in mind, we now propose a new
classification for disorders of hypersomnolence that is aimed to
improve diagnostic clarity and our understanding of disorders
causing hypersomnolence. Moreover, it will facilitate treatment
pathways for those who suffer from complaints of hypersomno-
lence in whom MSLT results have not necessarily fulfilled strict
diagnostic criteria and in whom sleep deprivation has been satis-
factorily excluded.
When OSA, chronic sleep deprivation and circadian rhythm
disorders have been effectively excluded, we suggest the creation of
three diagnostic categories, with levels of certainty, for central
disorders of hypersomnolence:
1) “Narcolepsy” replacing NT1 and NT2
2) “Idiopathic hypersomnia”
3) “Idiopathic excessive sleepiness”
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(idiopathic), familial, secondary (symptomatic), and narcolepsy
plus (hereditary forms with additional neurological symptoms)
forms [45]. We suggest discontinuing entities such as “hyper-
somnia due to medical disorder”, “hypersomnia due to substance
abuse”, or “hypersomnia associated with a psychiatric disorder”,
because in most cases it is generally unknown if the relationship is
truly causal or simply co-morbid [22,24]. Instead, medical disorders
and psychiatric disorders including substance abuse are considered
and listed as possible co-morbidities. This is in line with the deci-
sion made in ICSD3 to allow to diagnose insomnia independently
from the presence of amental disorder, amedical condition, or drug
or substance intake.
We suggest no changes to the diagnostic criteria for Kleine-
Levin syndrome because we focus on chronic disorders character-
ized by persistent and not remittent hypersomnolence.
3.1 Diagnostic criteria for narcolepsyLevel 1 A.
Definite EDS and or typical cataplexy* and CSF hypocretin deficiency
B.
EDS with typical cataplexy* and MSLT**: SL < 8 min and >1 SOREM (including nocturnal sleep)
Level 2 A.
Probable EDS with typical cataplexy and MSLT**: either SL < 8 min or >1
SOREM (including nocturnal sleep)
B.
EDS without typical cataplexy, but with HH and or SP and or disturbed nocturnal sleep; MSLT**:
SL < 5 min and >1 SOREM or SL < 8 min and >2 SOREMs (including nocturnal sleep) & HLA
DQB1*0602 positive; other causes of EDS need to be excluded [34,37,47,48,51]¶.
Familial*** - EDS with cataplexy or cataplexy-like episodes*; MSLT**: SL < 8 min and >1 SOREMP, and or
hypocretin deficiency; At least one first degree family member with similar complaints including cataplexy.
Symptomatic or secondary*** - EDS with cataplexy or cataplexy-like episodes*; the subject is known to suffer from Niemann Pick type C,
PradereWilli syndrome, or has a demonstrated lesion in the hypothalamus [45,46]. MSLT**: SL < 8 min and >1 SOREMP,
or hypocretin deficiency
* For definition, see 2.3.
** For an accurate interpretation of the MSLT, age should be taken into account [15,21].
*** In familial and secondary cases, both the presence of HLA DQB1*0602, and hypocretin deficiency in the CSF are less prevalent when compared to the idiopathic cases
[60,61].
¶ Diagnoses to be excluded are chronic sleep deficiency, circadian rhythm disorders and OSA. It is important to realize that there is a hierarchy. First exclude sleep deprivation
as cause of the complaints. If the complaints disappear after sleep extension, the complaint is cured and the diagnostic process is completed. If the complaint remains, circadian
rhythm disorders and OSA need to be excluded or treatedwhen theymight be responsible for the complaint. Only after completing these steps, and a remaining complaint that
qualifies for narcolepsy level 2B, the diagnostic process to assess whether the diagnostic criteria for narcolepsy level 2B aremet can be started. Symptomsmust be present daily
for at least 3 mo.Hypocretin deficiency is considered both the primary cause and
most specific biological marker for narcolepsy with cataplexy. The
presence of hypocretin deficiency in an individual is key to deter-
mining the level of certainty in this diagnostic classification. Cate-
gory 1A is therefore the most certain category. When applying the
strict interpretation of typical cataplexy which is mandatory, 98% of
the category 1B patients will be hypocretin deficient (familial and
secondary cases excluded, see below).
Hypocretin-1 measurement in the CSF, by adjusted radio im-
mune assay (RIA), is by far the most specific and sensitive test to
diagnose narcolepsy with (typical) cataplexy [47]. By definition it is
diagnostic for narcolepsy type 1 [1]. For the Stanford group, and
those who adjust to Stanford values by using Stanford reference
samples, the cut off is 110 pg/ml. In a clinical context, a value below
this concentration is considered diagnostic. Intermediate
hypocretin-1 levels between 110 and 200 pg/ml cannot exclude the
diagnosis but there are currently not enough data to alter cut off
levels to higher than 110 pg/ml. New methods of measuring CSF-
hypocretin for example by mass spectrometry are under develop-ment. Currently, the mentioned cut-off points cannot be used in
ELISA-basedmethods, whichmay showabnormally low values, and
hence falsely positive results.
In non-familial and non-secondary cases of narcolepsy type 1,
98% are HLA DQB1*0602 positive [48]. In narcolepsy type 2, this
percentage is much lower, averaging 40e50%. However, in the
group of narcolepsy type 2, HLA DQB1*0602 positivity is nearly
always seen if there is subsequent hypocretin deficiency or
symptoms of cataplexy [34]. In the general population, the pres-
ence of HLA DQB1*0602 is 15e38% [48,49]. Therefore, the pres-
ence of HLA is not helpful as a primary diagnostic tool but can
provide evidence to exclude it and for predicting eventual hypo-
cretin status.
Typical cataplexy is the clinical hallmark of narcolepsy type 1. It
is therefore very important to define typical cataplexy as precise as
possible. For this reason chapter two was added.
Additional support for hypocretin deficiency, beyond the pres-
ence of (typical) cataplexy:Subjective symptoms:
- ESS >14 [39,45,50].
- frequent daily naps that are typically short, refreshing and
associated with dream content [38,45].
Objective testing:
Considered to be “proven” support:
- MSLT: mean SL < 5 min [34,51].
- at least two SOREMPs [34].
- Short REM sleep latency nocturnal sleep (<15 min) [55]. The
evidence is strong in one study but there has never been an
independent confirmation and the specificity for narcolepsy
type 1 was very high but much less for hypocretin deficiency.
Moreover, the sensitivity of this finding is low.
- Consistent abnormal MSLT findings when repeating the MSLT
Suggested support but needs better validation:
1. Actigraphy with sleep logs (2 wk): strongly supports > 9 h sleep per night
or > 10 h sleep over 24 h on themajority of days, and 2. PSG recording (performed at
end actigraphy recording); preferably > 19 h of sleep in a 32-hrs clinical protocol
with standardized conditions [31], or, alternatively, a clinical or ambulant PSG
performed for 32-hrs (night 1 þ daytime þ night 2) allowing ad libitum sleep
showing > 19 h of sleep.
For level 2: not fulfilling criteria for level 1, but: 1. Actigraphywith sleep logs (2 wk):
strongly supports > 9 h of sleep over 24 h on the majority of days, and 2. PSG
(performed at end actigraphy recording): results on long continuous PSG (in sleep
lab or in ambulant conditions) support but do not fully meet the criterium of level 1
or is not performed as requested for level 1.
For both levels sleep efficiency for nocturnal sleep must be >85% (at least when
diagnostics are applied up to middle ages). If CSF hypocretin-1 measurement is
performed, the hypocretin-1 concentration should be in the normal range.
These criteria are essentially expert opinion although particularly the 32 h PSG
protocol is supported by a study.
Level 1 1. EDS complaint (as defined earlier)*
Definite* 2. Confirmed by PSG and MSLT: SL < 8 min**
3. Not fulfilling criteria for narcolepsy or IH
Level 2 1. EDS complaint (as defined earlier)*
Probable*: 2. MSLT: SL > 8 and <12 min
3. Not fulfilling criteria for narcolepsy or IH
Subtype 1 1. 1 SOREM on PSG/MSLT
“REM type” 2. Findings on SART may be normal or abnormal
Subtype 2 1. No SOREM on PSG/MSLT
“NREM type” 2. Normal findings on SART
Subtype 3 1. No SOREM on PSG/MSLT
“Attention type” 2. Abnormal findings on SART
Only level 2 is divided in subtypes.
* The complaint is present for at least three months.
** Those with inconsistent MSLT results over time will qualify for one of these
categories, unless criteria for narcolepsy or IH are met.
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- sleep stage sequence (REM sleep before occurrence stage 2 sleep
or frequent transition REM to stage 2) [27,52e54].
Relevant findings on a group level that need replication and vali-
dation to be added as diagnostic criteria are: sleep stage sequence/
transitions in nocturnal sleep [53,56] distribution of eye movement
during sleep stages [57], and power spectra analyses [58,59].
Narcolepsy phenotype [45]
- acute
- progressive
- chronic-stable
- chronic unstable
- other
Narcolepsy aetiology [45]
- idiopathic (sporadic)
- familial
- secondary (symptomatic)
- narcolepsy plus (hereditary forms with additional neurological
symptoms)
Severity of narcolepsy
A severity score has been suggested which could be elaborated
on [62].
To be taken into account.
- severity score of EDS (see 2.1.2)
- severity score of cataplexy (see 2.2)
- severity score for disturbance nocturnal sleep including the
severity of HH and or SP
- quality of life score
- score for severity of comorbidity
Frequent co-morbidities of definite and probable narcolepsy in
adults [45]
- Sleep disorders/disturbances: sleep disordered breathing, RLS/
PLMS, RBD, other parasomnias
- Medical disorders/disturbances: obesity, diabetes mellitus type
2, autonomic instability and cardiovascular disorders
- Psychiatric disorders/disturbances: anxiety, depression, psy-
chosocial problems
3.2 Diagnostic criteria for Idiopathic hypersomnia
By definition, sleep deprivation as primary cause is excluded.
Sleep apnea as cause needs to be excluded and in case of doubt, first
be treated.Level 1 1. The presence of ENS
Definite IH* 2. The ENS complaint is acquired**
3. There is objective evidence for increased sleep need using
actigraphy and PSG***
Level 2 1. The presence of ENS
Probable IH* 2. The ENS complaint is acquired**
3. There is objective support for increased sleep need using
actigraphy and PSG***
* The complaint must be present daily for at least 3 mo and all three criteria must be
fulfilled. Fatigue may be present but the excessive need for sleep must be the most
prominent complaint. There should be no concomitant major systemic symptoms or
factors such as fever or severe pain as these may indicate chronic inflammatory
conditions, infection, or auto-immune disorders. It is uncommon that the disorder
develops in or after middle-age.
Depression may be present and it is often appropriate to document it as a co-
morbidity.
** The point at which symptoms start or even if the disorder is truly acquiredmay be
difficult to establish when ENS is reported in (early) childhood [5,63].
*** For level 1, the criteria for objective confirmation are (both must be fulfilled):Severity criteria
See severity criteria of ENS paragraph 1.2.2. An existing and
recently published scale might be useful [64].
Comorbidities
- Depression, anxiety, chronic fatigue, circadian disorders, atten-
tion disorders are relatively frequently seen
3.3 Diagnostic criteria for Idiopathic excessive sleepiness
The diagnosis can only be made after exclusion of sleep apnea,
chronic sleep deprivation, and circadian disorders as likely causes
of the sleep-related complaints (see ¶ paragraph 3.1).
If the criteria for narcolepsy or IH are fulfilled, these diagnoses
should be made.*** The Sustained Attention to Response Task (SART) is a vigilance test to assess
sustained attention. It has been applied and validated in patients suffering from
hypersomnolence, ADHD and brain injury [7,65,66]. For the SART cut off values are
defined: for the instruction “prefer accuracy over speed”, the cut-off is 6 [67]. The
Psychomotor Vigilance Test (PVT) might be a good alternative for the SART but there
are no cut-off data validated for patients with hypersomnolence [68].Severity criteria
See severity criteria paragraph 1.2.1.
Comorbidities
- Depression, anxiety, chronic fatigue, attention disorders are
frequently seen.
Discussion
US clinicians were the first to create a classification of sleep and
arousal disorders in 1979 [69]. In 1990 the first edition of the
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lished, again with US physicians in the lead but representatives of
sleep disorders associations outside the US became involved. The
same holds true for the current edition of the classification, the
ICSD3, published in 2014. All subsequent editions provided im-
provements but nevertheless it is not uncommon to be difficult or
even impossible to make a proper diagnosis, including in people
consulting us because of convincing complaints of hypersomno-
lence. In the absence of a proper diagnosis people who might
deserve treatment may remain untreated. Discussions evoked by
these experiences ultimately resulted in this position paper.
Clinicians, researchers, and particularly members of classifica-
tion committees working in the field of hypersomnolence should
acknowledge the lack of knowledge and understanding of the
precise underlying neurobiological cause(s) of hypersomnolence
and therefore the uncertainty if disorders we currently define are
real disease entities. Moreover, the impact of lifestyle factors is
often poorly characterised or appreciated. In such a situation a
tendency to compensate the lack of knowledge by overemphasizing
the qualities and properties of any biological markers we currently
have should be resisted. It is our contention that the current clas-
sification system is unintentionally prone to this tendency. This is
not only a problem for patient care but may also prevent us from
identifying additional biomarkers for sleep disorders.
We therefore suggest a different approach. Differences between
the current and our approach:
- Our classification is much more complaint driven
- We emphasize that excessive daytime sleepiness is a multidi-
mensional complaint and qualitatively different from an
increased need for sleep.
- We use “hypersomnia” only to describe the presence of objec-
tified ENS.
- We acknowledge that attentional problems frequently accom-
pany disorders of hypersomnolence and isolated attention dis-
orders should be separated from sleep disorders.
- Sleep deprivation, OSA and circadian disorders need to be
initially excluded as primary causes of EDS. This allows the
differentiation of true central disorders of hypersomnolence
from disorders related to lifestyle disorders and sleep related
breathing disorders. In case of doubt the effect of increased
time in bed, a therapeutic test with CPAP, or circadian align-
ment must first be established. Guidelines from the National
Sleep Foundation may help to identify the presence of sleep
deprivation [70].
- We exclude possible confounders for changes in MSLT results
over time.
- If MSLT results change over time we emphasise this should not
necessarily have an immediate major impact on diagnostic
categories and affect patients' access to treatments, for example.
- Within our classification, patients can shift to more certain
levels of diagnosis over time. This will potentially provide more
insight in how disorders of hypersomnolence progress or
develop and will help to guide future research agenda.
- We allow and formalise a certain level of diagnostic uncertainty,
reflecting clinical reality in daily medical practice.
- There will be relatively few patients who will switch to a new
diagnosis as a result of a new classification.
We realize that implementation of our proposal will have
much impact on the current practices around the world. Differentinsurance systems and availability of the recommended tests (i.e.,
CSF orexin measurement, HLA typing, actigraphy, long term PSG
recording) may be an issue for clinicians in some countries.
However, our proposal is to move forward the field to improve
the knowledge and management of patients affected with hy-
persomnolence. The main objectives are 1. To diagnose homo-
geneous groups of patients affected with these different
hypersomnolence disorders, 2. To better understand the precise
underlying neurobiological of such conditions (i.e., other than
narcolepsy type 1), and finally 3. To improve the management of
these patients. A registry to validate and optimize our suggested
approach already exists in Europe within the European Narco-
lepsy Network (EU-NN) and could be extended to a global reg-
istry. In addition, studies to further validate the proposed
diagnostic tools in a prospective setting should be initiated in
several sleep labs around the world in the next few years. We
also call for an international task force to formulate guidelines for
the proper application of our suggested approach, The topics to
be at least included:
- how to define, assess and treat chronic sleep deprivation in a
practicable way
- what is the best and still feasible way to objectify ENS
For a better understanding of hypersomnolence disorders in
general we must initiate studies to get insight in:
- what determines an individual's sleep need and can we find
biological markers to measure this need
- what is the relation between hypersomnolence and depression
and how does it relate to the more studied close association
between insomnia and depression
- what is the exact inter-relation between sleepiness, fatigue and
disorders of attention
We are hopeful that further discussion will lead to a more
consistent, widely accepted and workable future classification of
central disorders of hypersomnolence. We also argue it will guide
and prioritise our research agenda. Finally, we expect that more
detailed attention to the multidimensional aspects of hypersom-
nolence complaints will facilitate and optimise clinical care tailored
to individual patients.Conclusion
We suggest the creation of a new consistent, complaint driven,
hierarchical classification for central disorders of hypersomno-
lence; containing levels of certainty, and giving diagnostic tests,
particularly the MSLT, a weighting based on its specificity and
sensitivity in the diagnostic context.
We propose and define three diagnostic categories (with levels
of certainty):
1. “Narcolepsy”
2. “Idiopathic hypersomnia”
3. “Idiopathic excessive sleepiness”
Except for narcolepsy, the diagnoses can only be made after
excluding sleep apnea, sleep deprivation and circadian disorders as
primary causes for hypersomnolence.
Practice points
1. “Hypersomnolence” is the overarching name for the
presence of EDS and/or ENS.
2. EDS and ENS are multidimensional and qualitatively
different complaints.
3. There are large gaps in our understanding of the precise
underlying neurobiological cause(s) of hypersomno-
lence and its associated disorders except for narcolepsy
type 1. Moreover, the impact of lifestyle factors is often
poorly characterised or appreciated.
4. Sleep deprivation, obstructive sleep apnea and circadian
disorders need to be initially excluded as primary causes
of hypersomnolence before considering a central disor-
der of hypersomnolence as cause of the complaint of
excessive daytime sleepiness (except for narcolepsywith
cataplexy/narcolepsy type 1).
5. For a reliable diagnosis of narcolepsy type 1, clear and
detailed criteria for the presence of typical cataplexy are
required.
6. The structure of a classification of sleep disorders,
including the chapter on central disorders of hypersom-
nolence, must be complaint driven and not a mixture of
complaint driven diagnoses and diagnoses solely based on
results of ancillary investigations (i.e., AHI, MSLT results).
7. We propose and define three diagnostic categories with
different levels of certainty and subtypes: 1/“Narco-
lepsy”; 2/“Idiopathic hypersomnia”, and 3/“Idiopathic
excessive sleepiness”.
Research agenda
We need to:
1. Understand what determines an individual's sleep need
and identify biological markers for it, as for disorders
characterised by EDS and ENS.
2. Develop and validate a guideline to identify and treat
chronic sleep deprivation as cause of excessive daytime
sleepiness.
3. Better understand how disorders of hypersomnolence
progress/develop over years.
4. Bridge the current gap between disorders of attention
and disorders of hypersomnolence.
5. Better define and understand the proposed association
between depression and hypersomnolence.
6. Better understand the inter-relation between sleepiness
and fatigue.
7. Look for new biomarkers.
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